Reuters logo
BRIEF-Prima BioMed announces second milestone payment for IMP701 program
July 16, 2017 / 11:17 PM / 5 months ago

BRIEF-Prima BioMed announces second milestone payment for IMP701 program

July 17 (Reuters) - Prima BioMed

* it will receive a second undisclosed significant clinical milestone payment from Novartis

* payment based on collaboration and licensing agreement between companies, relating to Prima’s imp701 lag-3 antibody Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below